EUCTR2008-000906-35-PT进行中（未招募）1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative Pneumonia
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 712
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Males and non-pregnant, non-lactating females, 18 years of age or
- •older. For females of child-bearing potential, one of the following
- •medically acceptable contraceptive methods must be used: or they agree to abstain from heterosexual intercourse while participating in the
- •study. One or more of these methods should be used during the study and continue for 30 days after completion of the antibiotic therapy.
- •a) Double-barrier methods of contraception (eg, condoms plus spermicidal foam)
- •b) Intrauterine contraceptive device
- •c) Approved pharmaceutical contraceptive product (eg, birth control pills or patches, long-term injectable or implantable hormonal
- •contraceptive)
- •2. Intubated and mechanically-ventilated (patients who have had a tracheotomy may be considered as possible study participants as long as they are being mechanically ventilated)
- •3. Diagnosis of pneumonia defined as presence of a new or progressive infiltrate(s) on chest radiograph
- •4. Presence of Gram-negative organism(s) indicated by:
- •a) Gram-stain OR
- •c) Suspected Gram-negative pathogen based on local surveillance data and medical history. Local surveillance data reflects the local patterns of bacterial prevalence and antibiotic resistance. Consideration should be given to the recent incidence of infections with Gram-negative
- •organisms in the hospital
- •5. Removed with amendment 5
- •6. Impaired oxygenation (within 48 hours prior to screening): a PaO2/FiO2 = 300 mmHg
- •7. CPIS greater than or equal to 6, (Section 15.3)
- •8. At least two risk factors for MDR organisms (MDR organism: an
- •organism resistant to representative agents in two or more of the
- •following antibiotic classes - beta-lactams, including penicillins,
- •cephalosporins, and monobactams; carbapenems; fluoroquinolones; and
- •aminoglycosides):
- •a) Antimicrobial therapy in the preceding two weeks
- •b) Current hospitalization greater than or equal to 5 days
- •c) High frequency (> 10%) of antibiotic resistance in the community or in the specific hospital unit
- •d) Immunosuppressive disease and/or therapy
- •e) Presence of the risk factors for HCAP
- •Hospitalization for two days or more in the preceding 90 days
- •Residence in a nursing home or extended care facility
- •Home infusion therapy (including antibiotics)
- •Chronic dialysis within 30 days
- •Home wound care
- •Family member with multidrug-resistant pathogen
- •9. Be willing and able to give written informed consent. If the patient is unable to give written informed consent, the patient's authorized representative may provide written consent as approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 278
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number o
排除标准
- •1. A history of hypersensitivity to amikacin or other aminoglyosides,
- •2. Has received antibiotic therapy for Gram-negative pneumonia for greater than 48 hours at the time of study drug administration. There should be as minimal a time delay as possible between randomization and first dose of study drug but up to 48 hours will be acceptable.
- •Exceptions: Systemic antibiotic therapy for more than 48 hours for gram negative infection prior to administration of first dose of study drug is
- •permitted if the infection is caused by pathogens that are resistant to the antimicrobial agent(s) used, or the patient's pneumonia is worsening.
- •3. Has primary lung cancer (including patients with small cell lung carcinoma/non-small cell lung carcinoma and patients with unknown histology) or another malignancy metastatic to the lungs or other known endobronchial obstructions. Exception: Note that patients with complete
- •resection of non-small cell lung carcinoma are eligible for the study.
- •4. Known or suspected active tuberculosis, cystic fibrosis, human
- •immunodeficiency virus (HIV) infection with CD 4 count < 200 cell/mm3
- •(HIV testing is not required as part of this protocol), or invasive fungal infection of the lung, lung abscess, or empyema.
- •5. Known or suspected bacteremia secondary to Staphylococcus aureus
- •6. Known or suspected neuromuscular disorders such as myasthenia gravis or parkinsonism
- •7. Has had a stroke within five days. Additionally, patients with stroke in the acute or sub-acute phase should not be enrolled if at least one or both of the following apply:
- •a) There is an increased risk of fatal brain edema as indicated by a history of hypertension or heart failure, major early computed
- •tomography (CT) hypodensity exceeding 50% of the middle cerebral artery territory, and/or involvement of additional vascular territories.
- •b) There is indication for deterioration based on comparison of patient's neurological condition within six hours of planned study drug dosing and
- •patient's neurological condition two days before, judged by applying the National Institute of Health (NIH) Stoke Scale (Section 15.4).
- •8. A positive urine and /or serum beta-human chorionic gonadotropin (B-hCG) pregnancy test
- •9. Burns greater than 40% of total body surface area
- •10. Patients with a serum creatinine > 2 mg/dL (177 µmol/L)
- •Exception: Patients with a serum creatinine > 2 mg/dL (177 µmol/L) and being treated with continuous renal replacement therapy
- •(continuous veno-venous hemofiltration [CVVH] and continuous venovenous hemofiltration with dialysis [CVVH-D]) or daily hemodialysis will
- •receive the aerosol study drug treatment (Section 8.4.6.1).
- •11. Neutropenia (Screening absolute neutrophil count [ANC] < 103 neutrophils/mm3)
- •12. Has been on mechanical ventilation for > 28 days (ie, current event should not be more than 28 continuous days). A patient is not considered extubated if cessation of mechanical ventilation lasts less than 24 hours.
- •13. Is participating in or has participated in other investigational
- •interventional studies within
研究者
相似试验
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With PrematureEjaculation and Concomitant Erectile Dysfunction Treated With aPhosphodiesterase-5 Inhibitor - COUPLEPremature ejaculationEUCTR2009-013616-12-FRJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative PneumoniaGram-negaive pneumoniaEUCTR2008-000906-35-CZBayer Schering Pharma AG712
进行中（未招募）
1 期
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated.Gram-negative pneumoniaMedDRA version: 20.1Level: LLTClassification code 10035701Term: Pneumonia gram-negative bacterial NOSSystem Organ Class: 100000004862EUCTR2008-000906-35-NLBayer AG362
已完成
3 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative PneumoniaGram-negative Pneumonia1000401810024970NL-OMON44738Bayer9
进行中（未招募）
不适用
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I DisorderBipolar I DisorderEUCTR2012-001935-30-CZElan Pharma International Ltd400